	US 12,077,546 B2
	Bicyclic pyridine derivative
Satoshi Adachi, Osaka (JP); Hidefumi Yoshinaga, Osaka (JP); Hajime Shibata, Osaka (JP); Yusuke Shioda, Osaka (JP); and Riko Nagahama, Osaka (JP)
Assigned to Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed on Nov. 10, 2023, as Appl. No. 18/506,804.
Application 18/506,804 is a continuation of application No. 18/554,525, previously published as PCT/JP2022/017396, filed on Apr. 8, 2022.
Claims priority of application No. 2021-066825 (JP), filed on Apr. 10, 2021; and application No. 2021-150394 (JP), filed on Sep. 15, 2021.
Prior Publication US 2024/0150370 A1, May 9, 2024
Int. Cl. C07D 471/04 (2006.01); A61P 25/00 (2006.01); C07D 213/65 (2006.01); C07D 215/12 (2006.01); C07D 221/04 (2006.01); C07D 401/06 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01)

CPC C07D 491/048 (2013.01) [A61P 25/00 (2018.01); C07D 213/65 (2013.01); C07D 215/12 (2013.01); C07D 221/04 (2013.01); C07D 401/06 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01)]

25 Claims

1. A compound selected from the group consisting of:

1-[(2R,3S)-6-fluoro-2-methyl-2,3-dihydrofuro[3,2-b]pyridin-3-yl]methanamine;

1-[(2R,3S)-2-methyl-2,3-dihydrofuro[3,2-b]pyridin-3-yl]methanamine;

N-methyl-1-[(2R,3S)-2-methyl-2,3-dihydrofuro[3,2-b]pyridin-3-yl]methanamine;

1-[(2R,3S)-6-fluoro-2-methyl-2,3-dihydrofuro[3,2-b]pyridin-3-yl]-N-methylmethanamine; and

1-[(2R,3S)-6-fluoro-2-methyl-2,3-dihydrofuro[3,2-b]pyridin-3-yl]-N-(2H3)methylmethanamine,

or a pharmaceutically acceptable salt thereof.